Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€8.47
13.12.21
-
13.12.22
-67.06%
14.12.22

Could be very worthwhile Investment >20% year
Revenue decline/stagnation expected
buy
Mirati Therapeutics Inc.

Start price
Target price
Perf. (%)
€47.20
07.12.22
-
07.12.23
-16.53%
10.12.22

Risky Investment
Canopy Growth Corp

Start price
Target price
Perf. (%)
€2.55
13.10.22
€2.30
13.10.23
42.55%
19.11.22

Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Risky balance sheet
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€13.55
13.11.21
-
13.11.22
-69.88%
14.11.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Innovative
Future proof or reliable business model
buy
Orpea Nom.

Start price
Target price
Perf. (%)
€9.52
26.10.22
-
26.10.23
-30.01%
30.10.22

Could be very worthwhile Investment >20% year
buy
Orpea Nom.

Start price
Target price
Perf. (%)
€7.95
28.10.22
-
28.10.23
-16.20%
29.10.22

Could be very worthwhile Investment >20% year
buy
Davita Inc.

Start price
Target price
Perf. (%)
€73.02
28.10.22
-
0.45%
28.10.22

Risky Investment
buy
Korian S.A.

Start price
Target price
Perf. (%)
€28.30
17.10.21
€30.00
17.10.22
-62.44%
18.10.22

Could be worthwhile Investment >10% per year
buy
Galapagos N.V.

Start price
Target price
Perf. (%)
€45.08
13.10.21
€46.00
13.10.22
-0.18%
14.10.22

Could be worthwhile Investment >10% per year
buy
Galapagos N.V.

Start price
Target price
Perf. (%)
€45.08
13.10.21
€46.00
13.10.22
-0.18%
14.10.22

Could be worthwhile Investment >10% per year
buy
Canopy Growth Corp

Start price
Target price
Perf. (%)
€2.91
03.08.22
€3.30
03.08.23
-12.37%
13.10.22

Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Risky balance sheet
buy
Orpea Nom.

Start price
Target price
Perf. (%)
€101.00
28.09.21
€105.00
28.09.22
-87.18%
29.09.22

Could be worthwhile Investment >10% per year
buy
Acceleron Pharma Inc.

Start price
Target price
Perf. (%)
€158.00
28.09.21
-
28.09.22
0.63%
28.09.22

buy
Evotec SE

Start price
Target price
Perf. (%)
€43.60
21.09.21
-
21.09.22
-57.56%
21.09.22

buy
MorphoSys AG

Start price
Target price
Perf. (%)
€30.80
08.01.22
-
08.01.26
-46.20%
05.09.22

Probably not worthwhile Investment
buy
MorphoSys AG

Start price
Target price
Perf. (%)
€30.80
08.01.22
-
08.01.26
-46.20%
05.09.22

Probably not worthwhile Investment
buy
Mirati Therapeutics Inc.

Start price
Target price
Perf. (%)
€76.50
21.08.22
€230.00
21.08.23
6.54%
04.09.22

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Probably not worthwhile Investment
Lower EBIT Margin than peer group
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€214.90
21.08.22
€87.00
21.08.23
-3.44%
04.09.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
MorphoSys AG

Start price
Target price
Perf. (%)
€33.28
23.12.21
-
23.12.22
-41.87%
25.08.22

buy
MorphoSys AG

Start price
Target price
Perf. (%)
€33.28
23.12.21
-
23.12.22
-41.87%
25.08.22

buy
Tandem Diabetes Care Inc

Start price
Target price
Perf. (%)
€91.50
10.08.21
-
10.08.22
-42.25%
10.08.22

buy
MorphoSys AG

Start price
Target price
Perf. (%)
€23.24
04.08.22
€30.00
04.08.23
-3.31%
06.08.22

buy
MorphoSys AG

Start price
Target price
Perf. (%)
€23.24
04.08.22
€30.00
04.08.23
-3.31%
06.08.22

buy
Global Blood Therapeutics Inc

Start price
Target price
Perf. (%)
€33.09
30.10.21
€45.00
31.12.23
94.65%
05.08.22

Could be very worthwhile Investment >20% year
buy
Evotec SE

Start price
Target price
Perf. (%)
€24.04
04.07.22
€30.00
04.08.22
19.97%
05.08.22